Long-term incidence and prognostic factors of the progression of new coronary lesions in Japanese coronary artery disease patients after percutaneous coronary intervention

Heart and Vessels

Volumn 29, Issue 4, 2014, Pages 437-442

  Kaneko, Hidehiro ^a   Yajima, Junji ^a   Oikawa, Yuji ^a   Tanaka, Shingo ^a   Fukamachi, Daisuke ^a   Suzuki, Shinya ^a   Sagara, Koichi ^a   Otsuka, Takayuki ^a   Matsuno, Shunsuke ^a   Kano, Hiroto ^a   Uejima, Tokuhisa ^a   Koike, Akira ^a   Nagashima, Kazuyuki ^a   Kirigaya, Hajime ^a   Sawada, Hitoshi ^a   Aizawa, Tadanori ^a   Yamashita, Takeshi ^a  

^a THE CARDIOVASCULAR INSTITUTE   (Japan)

Author keywords

High density lipoprotein cholesterol; Insulin; Japanese; New culprit coronary artery lesion; Percutaneous coronary intervention

Indexed keywords

HIGH DENSITY LIPOPROTEIN; INSULIN; ANTIDIABETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE COURSE; DRUG USE; FEMALE; HUMAN; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; OBESITY; PERCUTANEOUS CORONARY INTERVENTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SURVIVAL RATE; ADVERSE EFFECTS; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CHI SQUARE DISTRIBUTION; COMORBIDITY; DIABETES MELLITUS; DYSLIPIDEMIAS; EPIDEMIOLOGY; ETHNOLOGY; JAPAN; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; TIME; TREATMENT OUTCOME;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CHI-SQUARE DISTRIBUTION; CHOLESTEROL, HDL; COMORBIDITY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE PROGRESSION; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; INSULIN; JAPAN; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PREVALENCE; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84904119280     PISSN: 09108327     EISSN: 16152573     Source Type: Journal    
DOI: 10.1007/s00380-013-0382-6     Document Type: Article

References (31)

1. Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, Mehran R (2010) In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol 56:1897-1907
2. Kastrati A, Dibra A, Mehilli J, Mayer S, Pinieck S, Pache J, Dirschinger J, Schomig A (2006) Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents. Circulation 113:2293-2300 (Pubitemid 43947975)
3. Elezi S, Kastrati A, Pache J, Wehinger A, Hadamitzky M, Dirschinger J, Neumann FJ, Schomig A (1998) Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 32:1866-1873 (Pubitemid 29010448)
4. Kastrati A, Schomig A, Elezi S, Schuhlen H, Dirschinger J, Hadamitzky M, Wehinger A, Hausleiter J, Walter H, Neumann FJ (1997) Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol 30:1428-1436 (Pubitemid 27486458)
5. Suzuki S, Sagara K, Otsuka T, Matsuno S, Funada R, Uejima T, Oikawa Y, Koike A, Nagashima K, Kirigaya H, Yajima J, Sawada H, Aizawa T, Yamashita T (2012) Gender-specific relationship between serum uric acid level and atrial fibrillation prevalence. Circ J 76:607-611
6. Suzuki S, Yamashita T, Ohtsuka T, Sagara K, Uejima T, Oikawa Y, Yajima J, Koike A, Nagashima K, Kirigaya H, Ogasawara K, Sawada H, Aizawa T (2008) Prevalence and prognosis of patients with atrial fibrillation in Japan: a prospective cohort of Shinken Database 2004. Circ J 72:914-920 (Pubitemid 351879911)
7. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53:982-992
8. Tonelli M, Jose P, Curhan G, Sacks F, Braunwald E, Pfeffer M (2006) Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial. BMJ 332:1426
9. Allison DB, Fontaine KR, Manson JE, Stevens J, VanItallie TB (1999) Annual deaths attributable to obesity in the United States. JAMA 282:1530-1538 (Pubitemid 29504046)
10. St Jeor ST, Brownell KD, Atkinson RL, Bouchard C, Dwyer J, Foreyt JP, Heber D, Kris-Etherton P, Stern JS, Willett W (1993) Obesity. Workshop III. AHA Prevention Conference III. Behavior change and compliance: keys to improving cardiovascular health. Circulation 88:1391-1396
11. Park MW, Seung KB, Kim PJ, Park HJ, Yoon SG, Baek JY, Koh YS, Jung HO, Chang K, Kim HY, Baek SH (2009) Long-term percutaneous coronary intervention rates and associated independent predictors for progression of nonintervened nonculprit coronary lesions. Am J Cardiol 104:648-652
12. Glaser R, Selzer F, Faxon DP, Laskey WK, Cohen HA, Slater J, Detre KM, Wilensky RL (2005) Clinical progression of incidental, asymptomatic lesions discovered during culprit vessel coronary intervention. Circulation 111:143-149 (Pubitemid 40139724)
13. Kimura T, Morimoto T, Nakagawa Y, Kawai K, Miyazaki S, Muramatsu T, Shiode N, Namura M, Sone T, Oshima S, Nishikawa H, Hiasa Y, Hayashi Y, Nobuyoshi M, Mitudo K (2012) Very Late Stent Thrombosis And Late Target Lesion Revascularization After Sirolimus-Eluting Stent Implantation: Five-Year Outcome Of The j-Cypher Registry. Circulation 125:584-591
14. Gordon DJ, Rifkind BM (1989) High-density lipoprotein - the clinical implications of recent studies. N Engl J Med 321:1311-1316 (Pubitemid 19267219)
15. Castelli WP (1983) Cardiovascular disease and multifactorial risk: challenge of the 1980s. Am Heart J 106:1191-1200
16. Glueck CJ, Gartside P, Fallat RW, Sielski J, Steiner PM (1976) Longevity syndromes: familial hypobeta and familial hyperalpha lipoproteinemia. J Lab Clin Med 88:941-957 (Pubitemid 8002485)
17. Rosenson RS, Brewer HB Jr, Davidson WS, Fayad ZA, Fuster V, Goldstein J, Hellerstein M, Jiang XC, Phillips MC, Rader DJ, Remaley AT, Rothblat GH, Tall AR, Yvan-Charvet L (2012) Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation 125:1905-1919
18. Oram JF, Johnson CJ, Brown TA (1987) Interaction of high-density lipoprotein with its receptor on cultured fibroblasts and macrophages. Evidence for reversible binding at the cell surface without internalization. J Biol Chem 262:2405-2410
19. Kuhn FE, Mohler ER, Satler LF, Reagan K, Lu DY, Rackley CE (1991) Effects of high-density lipoprotein on acetylcholine-induced coronary vasoreactivity. Am J Cardiol 68:1425-1430
20. Kontush A, Chantepie S, Chapman MJ (2003) Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol 23:1881-1888 (Pubitemid 37254879)
21. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM (2004) Antiinflammatory properties of HDL. Circ Res 95:764-772 (Pubitemid 39390578)
22. Saku K, Ahmad M, Glas-Greenwalt P, Kashyap ML (1985) Activation of fibrinolysis by apolipoproteins of high-density lipoproteins in man. Thromb Res 39:1-8 (Pubitemid 15008435)
23. Griffin JH, Kojima K, Banka CL, Curtiss LK, Fernandez JA (1999) High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J Clin Invest 103:219-227 (Pubitemid 29053140)
24. Epand RM, Stafford A, Leon B, Lock PE, Tytler EM, Segrest JP, Anantharamaiah GM (1994) HDL and apolipoprotein A-I protect erythrocytes against the generation of procoagulant activity. Arterioscler Thromb 14:1775-1783
25. Aoyama T, Yui Y, Morishita H, Kawai C (1990) Prostaglandin I2 half-life regulated by high-density lipoprotein is decreased in acute myocardial infarction and unstable angina pectoris. Circulation 81:1784-1791 (Pubitemid 20183827)
26. National Cholesterol Education Program Coordinating Committee (2002) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106:3143-3421
27. Norhammar A, Lagerqvist B, Saleh N (2010) Long-term mortality after PCI in patients with diabetes mellitus: results from the Swedish Coronary Angiography and Angioplasty Registry. Euro Intervention 5:891-897
28. Anselmino M, Ohrvik J, Malmberg K, Standl E, Ryden L (2008) Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart. Eur Heart J 29:177-184
29. McGuire DK, Newby LK, Bhapkar MV, Moliterno DJ, Hochman JS, Klein WW, Weaver WD, Pfisterer M, Corbalan R, Dellborg M, Granger CB, Van De Werf F, Topol EJ, Califf RM (2004) Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes. Am Heart J 147:246-252 (Pubitemid 38176824)
30. Arcaro G, Cretti A, Balzano S, Lechi A, Muggeo M, Bonora E, Bonadonna RC (2002) Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulation 105:576-582 (Pubitemid 34123431)
31. Angiolillo DJ, Bernardo E, Ramirez C, Costa MA, Sabate M, Jimenez-Quevedo P, Hernandez R, Moreno R, Escaned J, Alfonso F, Banuelos C, Bass TA, Macaya C, Fernandez-Ortiz A (2006) Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol 48:298-304 (Pubitemid 44026661)